Abstract FK506 (Tacrolimus), isolated from Streptomyces tsukubaenis is a powerful
immunosuppressant shown to inhibit T cell activation. FK506 mediated immunosuppression …

The FK506 binding protein (FKBP) family of proteins provide an interesting series of drug
targets since different isoforms modulate diverse cellular pathways. There are therapeutic …

FK506 binding proteins (FKBPs) are a family of highly conserved proteins in eukaryotes. The
prototype of this protein family, FKBP12, is the binding partner for immunosuppressive drugs …

In recent years, many members of the FK506-binding protein (FKBP) family were
increasingly linked to various diseases. The binding domain of FKBPs differs only in a few …

Abstract FK506‐binding proteins (FKBPs) are promising targets for a variety of disorders and
infectious diseases. High FKBP occupancy is thought to be necessary for ligands to …

The human Hsp90 co-chaperone FKBP52 belongs to the family of FK506-binding proteins,
which act as peptidyl-prolyl isomerases. FKBP52 specifically enhances the signaling of …

FK506 binding (FKBP) proteins are part of the highly conserved immunophilin family and its
members have fundamental roles in the regulation of signalling pathways involved in …

The FK506‐binding proteins (FKBPs) are a unique group of chaperones found in a wide
variety of organisms. They perform a number of cellular functions including protein folding …

Multiple intracellular receptors of the FK506 binding protein (FKBP) family of peptidylprolyl
cis/trans-isomerases are potential targets for the immunosuppressive drug FK506. Inhibition …

Background FK506-binding proteins (FKBPs) have become the subject of considerable
interest in several fields, leading to the identification of several cellular and molecular …